Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita Inc. DVA has been gaining from strong execution across its Integrated Kidney Care (IKC) platform, improving treatment volumes and investments in technology and clinical innovation. The optimism is led by solid first-quarter 2026 results and higher full-year guidance. However, intense competition, commercial payer-mix pressures and regulatory and macroeconomic uncertainty remain key concerns.

Year to date, this Zacks Rank #3 (Hold) stock rallied 58.5%, outperforming the industry’s 22% growth and the S&P 500’s 11.6% gain.

The renowned global comprehensive kidney care provider has a market capitalization of $11.74 billion. The company projects 26.5% growth over the next five years and expects to maintain its strong performance going forward. DaVita’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 0.14%.

Image Source: Zacks Investment Research

Growth Drivers for DVA Stock

Expanding Value-Based Kidney Care: DaVita’s Integrated Kidney Care (IKC) platform remains a key growth engine, with risk-based patients increasing to 64,900 in second-quarter 2026 from 62,600 in the first quarter, representing approximately $5.8 billion in annualized medical spend. DaVita recently expanded its relationship with Humana through a new value-based agreement covering more than 10,000 Medicare Advantage members with CKD stages 3B–5. The partnership moves care earlier in the disease journey, aiming to delay or prevent dialysis, reduce hospitalizations and improve outcomes. Expanding IKC enrollment, medical spend under management and Medicare Advantage partnerships can create a larger, recurring value-based revenue opportunity while strengthening DaVita’s position in earlier-stage kidney care.

Strengthening Core Dialysis & Home Care: DaVita’s U.S. dialysis business continues to provide a stable operating foundation, with 7.23 million treatments delivered in second-quarter 2026 and revenue per treatment of $415.9. Management expects 2026 treatment growth toward the top end of its prior guidance, supported partly by improving mortality trends. The company is also prioritizing home hemodialysis and peritoneal dialysis, while its early-2026 minority investment in Elara Caring is designed to expand home-based support for ESKD patients and potentially reduce hospitalizations and missed treatments. Stable dialysis demand combined with expanding home-based care supports treatment volumes, patient retention and opportunities to capture a larger share of the kidney-care continuum.

Clinical Innovation & Earlier Intervention: DaVita continues to use clinical innovation to improve outcomes and support long-term growth. Its MODEL and MEMOIRS initiatives are evaluating advanced dialyzer technologies and their impact on survival and patient-reported outcomes. Meanwhile, the Humana partnership expands DaVita’s coordinated, whole-person approach to CKD, supported by a network of approximately 3,000 value-based nephrologist partners. The model addresses kidney, cardiovascular and metabolic health while providing education, treatment planning and support around home dialysis and transplantation. Better clinical outcomes and earlier intervention can reduce costly complications, improve patient engagement and strengthen DaVita’s ability to expand value-based contracts.

Downsides of DVA Stock

Competitive Pressure: DaVita faces intense competition across its U.S. dialysis operations from large providers such as Fresenius Medical Care, private equity-backed kidney care companies, independent nephrologists and new market entrants. Competition extends beyond traditional dialysis into integrated kidney care, value-based care and transplant services, where technology-driven and well-capitalized healthcare companies are introducing new treatment and care-delivery models. This pressure can make it harder for DaVita to secure attractive acquisitions, maintain patient volumes and build physician relationships. Rising competition could pressure market share, pricing, patient growth and acquisition opportunities, limiting DaVita’s long-term earnings growth.

Payer-Mix Headwinds: DaVita’s profitability remains sensitive to its relatively small but higher-paying commercial insurance population. Commercial mix remained in the high teens during the first half of 2026, while management expects an approximately $40 million headwind from ACA effectuation and mix in 2026, increasing to an estimated $70 million impact in 2027. Revenue per treatment is also expected to face pressure in the second half of 2026 due to a weaker commercial mix, lower phosphate binder revenues and difficult comparisons with late-2025 claim resolutions. A deteriorating payer mix and lower commercial reimbursement can weigh on revenue per treatment and margins even when dialysis volumes remain stable.

Regulatory & Macro Risks: DaVita operates under extensive and evolving federal, state and international healthcare regulations, including Medicare and Medicaid reimbursement requirements. Changes to Medicaid eligibility, payment models, healthcare transparency rules and government enforcement could increase compliance costs and financial exposure. Also, inflation, labor shortages, interest-rate volatility, tariffs, supply-chain disruptions and geopolitical uncertainty could raise operating expenses. Economic weakness may further shift patients from higher-paying commercial insurance toward lower-paying government coverage or uninsured status. Regulatory changes and macroeconomic pressures can increase costs, reduce reimbursement and create greater uncertainty around DaVita’s earnings and cash generation.

DaVita Inc. Price

DaVita Inc. price | DaVita Inc. Quote

Estimate Trend

DaVita is witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for earnings per share has remained unchanged at $14.57.

The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $3.53 billion, indicating a 3.2% uptick from the year-ago quarter’s reported number. The consensus mark for earnings is pegged at $3.78 per share, implying 50.6% year-over-year growth.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Veracyte VCYT, Globus Medical GMED and West Pharmaceutical WST.

Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently sporting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research